By Ayesha Khan, MBA The rapid rise of glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide, tirzepatide, liraglutide, and related medications, has transformed the treatment landscape for obesity and type 2 diabetes
Tf ligand-receptor-mediated exenatide-Zn(2+) complex oral-delivery system for penetration enhancement of exenatide
FFAs induce oxidative stress by generating ROS, which promote lipid peroxidation and activate cell death pathways, thereby exacerbating the vicious cycle between mitochondrial failure and ER stress (Khoi et al., 2024
Comparison of medication adherence and persistence in type 2 diabetes: a systematic review and meta-analysis
Wegovy and Ozempic both contain semaglutide, but they are authorised for different primary purposes